Table 1. Correlations between JARID2 expression in HCC tissues and clinicopathologic variables of HCC patients in training and validation cohort.

Clinicopathologic variable	Training cohort				Validation Cohort
	No.	JARID2 expression levels			JARID2 expression level
		Low	High	P value	No.	Low	High	P value
Gender
Female	13	5	8	0.874	16	6	10	0.413
Male	103	42	61		50	22	28
Age (years)
≤ 60	93	39	54	0.805	56	24	32	0.295
> 60	23	8	15		10	4	6
AFP(ng/mL)
≤ 20	56	24	32	0.620	23	10	13	0.899
> 20	60	23	37		43	18	25
HBsAg
Negative	29	12	17	0.913	18	6	12	0.182
Positive	87	35	52		48	22	26
Liver cirrhosis
Absence	31	14	17	0.538	29	13	16	0.725
Presence	85	33	52		37	15	22
Child-Pugh classification
A	102	41	61	0.849	59	24	35	0.668
B	14	6	8		7	4	3
Tumor number
Solitary	56	31	25	0.002	32	21	11	< 0.001
Multiple	60	16	44		34	7	27
Tumor size
≤ 5 cm	39	13	26	0.262	17	8	9	0.654
> 5 cm	77	34	43		49	20	29
Capsular formation
Presence	52	26	26	0.061	36	13	23	0.672
Absence	64	21	43		30	15	15
Microvascular invasion
Absence	68	36	32	0.001	41	23	18	0.004
Presence	48	11	37		25	5	20
Edmondson-Steiner grade
Low grade (I and II)	36	22	14	0.004	30	19	11	0.002
High grade (III and IV)	80	25	55		36	9	27
HCC subtype				0.007#				0.001#
SHCC	24	14	10	0.698##	14	9	5	0.890##
SLHCC	32	17	15	0.006*	18	12	6	0.004*
NHCC	60	16	44	0.012**	34	7	27	0.001**
TNM Stage
I	51	26	25	0.042	27	17	10	0.005
II–III	65	21	44		39	11	28
BCLC Stage
0–A	49	25	24	0.049	21	14	7	0.006
B–C	67	22	45		45	14	31

Abbreviations: AFP, alpha-fetoprotein; TNM, tumor node metastasis; BCLC, Barcelona Clinic Liver Cancer; SHCC, small hepatocellular carcinoma; SLHCC, solitary large hepatocellular carcinoma; NHCC, nodular hepatocellular carcinoma;

^#SHCC vs. SLHCC vs. NHCC;

^##SHCC vs. SLHCC;

^*SHCC vs. NHCC;

^**SLHCC vs. NHCC.